PBAC Public Summary Documents – May 2025
Page last updated: 29 August 2025
Public Summary Documents relating to the May 2025 PBAC meeting.
- Alectinib: Capsule 150 mg; Alecensa®
- Bimekizumab: Injection 160 mg in 1 mL single use pre-filled pen, Injection 160 mg in 1 mL single use pre-filled syringe, Injection 320 mg in 2 mL single use pre-filled pen, Injection 320 mg in 2 mL single use pre-filled syringe; Bimzelx®
- Dostarlimab: Solution concentrate for I.V. infusion 500 mg in 10 mL; Jemperli®
- Durvalumab and Tremelimumab: Durvalumab: Solution concentrate for I.V. infusion 120 mg in 2.4 mL, Solution concentrate for I.V. infusion 500 mg in 10 mL; Imfinzi®; Tremelimumab: Solution concentrate for I.V. infusion 300 mg in 15 mL; Imjudo®
- Empagliflozin: Tablet 10 mg; Jardiance®
- Etonogestrel with Ethinylestradiol: Vaginal ring containing etonogestrel 11.7 mg with ethinylestradiol 2.7 mg; NuvaRing®
- Guselkumab: Injection 100 mg in 1 mL single use pre-filled pen; Tremfya®
- Omalizumab: Injection 75 mg in 0.5 mL single dose pre-filled syringe, Injection 150 mg in 1 mL single dose pre-filled syringe, Injection 300 mg in 2 mL single dose pre-filled syringe, Injection 75 mg in 0.5 mL single dose pre-filled pen, Injection 150 mg in 1 mL single dose pre-filled pen, Injection 300 mg in 2 mL single dose pre-filled pen; Xolair®
- Pegcetacoplan: Solution for subcutaneous infusion 1,080 mg in 20 mL; Empaveli®
- Pioglitazone: Tablet 15 mg (as hydrochloride), Tablet 30 mg (as hydrochloride), Tablet 45 mg (as hydrochloride); Actos®
- Ranibizumab: Solution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringe, Solution for intravitreal injection 2.3 mg in 0.23 mL; Lucentis®
- Repotrectinib: Capsule 40 mg, Capsule 160 mg; Augtyro™
- Ublituximab: Solution concentrate for I.V. infusion 150 mg in 6 mL (25 mg per mL); Briumvi®
The following Public Summary Documents have been updated:
